other material
confidence high
sentiment positive
materiality 0.90
NewAmsterdam Pharma Reports Phase 3 BROADWAY and TANDEM Data Published in NEJM and Lancet
NewAmsterdam Pharma Co N.V.
- BROADWAY trial showed 33% LDL-C reduction (p<0.0001) vs placebo and a 21% relative reduction in MACE (HR=0.79).
- TANDEM trial fixed-dose combination of obicetrapib and ezetimibe achieved 48.6% LDL-C reduction vs placebo (p<0.001).
- Pooled Lp(a) analysis across three Phase 3 trials showed a median placebo-adjusted reduction of 45% at 12 weeks.
- Obicetrapib plus moderate statins lowered LDL-C by 69% (atorvastatin 20 mg) and 64% (rosuvastatin 10 mg) in a Phase 2 trial.
- Phase 2 data showed synergy in plaque prevention: combination of obicetrapib and ezetimibe reduced plaque formation by 98% vs 78% independently.